ELMWOOD PARK, N.J.,
April 27, 2021 /PRNewswire/
-- BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ:OPK), announced its renewal as the COVID-19 testing
provider for Major League Soccer (MLS), which began on April 17 along with the 2021 MLS season.
BioReference announced its renewal as the COVID-19 testing provider
for Major League Soccer (MLS) for the second year.
Similar to BioReference's role as the testing provider for the
MLS is Back Tournament, BioReference is providing laboratory-based
PCR COVID-19 testing as well as point-of-care (rapid) COVID-19
testing to players, match officials, and League staff for 13 Club
teams.
In addition to providing testing to players, match officials,
and staff, BioReference is working with the New England Revolution
to test fans with field level seats prior to home games, which
began with the Revolution's first season home game at Gillette
Stadium on April 24.
"MLS was the first major sports league to utilize COVID-19
testing from BioReference in 2020 during its MLS is Back Tournament
in Orlando," said Jon R. Cohen, M.D., Executive Chairman of
BioReference Laboratories. "We continue to be impressed by the
diligent work done by MLS' leadership to refine COVID-19 mitigation strategies and
prioritize testing, in maintaining
the goal of providing the safest possible environment for the
players, coaches, staff and now fans as the 2021 season
begins."
To learn more about BioReference's COVID-19 testing, please
visit: https://www.bioreference.com/coronavirus/.
About BioReference Laboratories, Inc.
BioReference Laboratories, Inc., is one of the largest full service
specialty laboratories in the United
States that gives healthcare providers and patients the
power to make confident healthcare decisions. With a focus on
genetics, oncology, urology and women's health, BioReference offers
comprehensive test solutions and unparalleled expertise based on a
40 year legacy of proven science. The company is in-network with
the largest health plans in the United
States, serves approximately 19 million patients annually,
operates a network of 11 laboratory locations, and is backed by a
medical staff of more than 300 M.D.,
D.O., Ph.D., genetic counselors and other professional clinical and
scientific personnel. With a national footprint and niche market
experience, BioReference provides credible and innovative solutions
that meet the needs of employers, governmental agencies,
educational systems, hospitals and health systems, correctional
institutions, sports leagues, travel and leisure industries, and
retail markets. BioReference provides industry-leading custom
solutions for COVID-19, including point-of-care testing and
large-scale screening programs.
https://www.bioreference.com/
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company
that seeks to establish industry-leading positions in large,
rapidly growing markets by leveraging its discovery, development,
and commercialization expertise and novel and proprietary
technologies. For more information,
visit www.opko.com.
Contacts:
Media Inquiries
Hillary Titus, 201-406-9968
htitus@bioreference.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/major-league-soccer-renews-with-bioreference-laboratories-as-covid-19-testing-provider-for-second-year-301277398.html
SOURCE BioReference Laboratories, Inc